Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.
Contact | 
Explore Technologies



Anti-CCRL2 Monoclonal Antibody, BZ2E3 cell line


Stanford Reference:

02-059


Abstract


Dr. Brian Zabel and Prof. Eugene Butcher have developed rat monoclonal antibodies (clones BZ2E3 and BZ5B8, rIgG2aκ isotype) to the mouse chemokine (CC motif) receptor-like 2 (CCRL2) protein. CCRL2 (formerly known as L-CCR) is expressed on mast cells, activated macrophages, and endothelial cells. It binds the leukocyte chemoattractant chemerin without triggering classical GPCR signaling, providing a specific mechanism for local enrichment of chemerin at inflammatory sites. CCRL2 presents active chemerin to leukocytes expressing the chemoattractant receptor CMKLR1/Chemr23. These anti-CCRL2 antibodies can be used in wide variety of assays to study leukocytes and immune response. Chemerin can block anti-CCRL2 antibody binding.


Applications


  • Research - antibodies are fully validated for flow cytometry and immunofluorescence.

Publications



Related Web Links



Innovators & Portfolio



Date Released

 7/10/2014 12:00
 

Licensing Contact


Agreements Group
Request Info

79-066 Mouse Anti-Human Hybridomas: 12E7, L243, L17F12, L368
82-068 Hybridomas 3B12, an Anti-Human Leucocyte Reagent, and Hybridoma 4H9, an Anti-Human T Cell Reagent
83-007 Anti-Leu-12 (CD19) Monoclonal Antibody, 4G7

more technologies »

Related Keywords


LS: Research Tool: flow cytometry   immune system profiling   LS: research tool: antibody   immunoassay   immunoreagents   monoclonal antibodies   immunocytometry   chemokine   Chemokine and Receptor Involved   chemokine targets   immune response   chemerin